Design Therapeutics Gains 19%, Insider Trades Reap Benefit
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
With 34% Ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) Has Piqued the Interest of Institutional Investors
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital